Rapport Therapeutics News and Activities

Rapport Therapeutics is one of the...

• Russell 3000;
• TOB Iconic 10,000.

Rapport Therapeutics is a company listed under the stock ticker RAPP (US).

Acquisition, funding and merger involving Rapport Therapeutics.

• Rapport Therapeutics has just announced a $154 Million fundraising (posted on June 11 2024).

View the org chart displaying its 42 main executives

Most searched biographies at Rapport Therapeutics

• Abraham Ceesay, Chief Executive Officer
• Wendy Young, Director
• Paul Silva, Director

Popular executive movements at Rapport Therapeutics

• Irena Webster has joined the company as Senior Vice President, Head of Development Operations  (posted on May 6 2026).

Create your alert
to follow the executive moves at Rapport Therapeutics.

Rapport Therapeutics has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by Rapport Therapeutics

• Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference » Rapport Therapeutics, Inc.
• Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update » Rapport Therapeutics, Inc.
• Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting » Rapport Therapeutics, Inc.
• Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting » Rapport Therapeutics, Inc.
• Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update » Rapport Therapeutics, Inc.
• Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China » Rapport Therapeutics, Inc.
• Rapport Therapeutics to Participate in Upcoming Investor Conferences » Rapport Therapeutics, Inc.
• Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline » Rapport Therapeutics, Inc.
• Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures » Rapport Therapeutics, Inc.
• Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference » Rapport Therapeutics, Inc.
• View more press releases Close

Social media about Rapport Therapeutics

• Rapport Therapeutics on Wikipedia, Google News & Yahoo Finance
• Rapport Therapeutics on LinkedIn, X (Twitter) & YouTube